Study of the Efficacy and Safety of MEDI4893

Completed · Phase 2 · Has a placebo group

Conditions studied: Staphylococcus Aureus Pneumonia

In brief

Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients

Key facts

Study ID: NCT02296320
Run by: MedImmune LLC
People needed: 213
Starts: 2014-10-10
Expected to finish: 2018-10-02
Last updated by the study team: 2019-12-23

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Colonized with Staphylococcus aureus, expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.

You may not qualify if…

Staphylococcal disease at randomisation; lung injury score consistent with pneumonia; current lung disease; chronic tracheostomy patients; currently receiving systemic anti-staphylococcal antibiotics; moribund patients.

Where it is running

Research Site — Atlanta, Georgia, United States
Research Site — Detroit, Michigan, United States
Research Site — Arlon, Belgium
Research Site — Brussels, Belgium
Research Site — La Louvière, Belgium
Research Site — Lodelinsart, Belgium
Research Site — Yvoir, Belgium
Research Site — Brno, Czechia
Research Site — Děčín, Czechia
Research Site — Kyjov, Czechia
Research Site — Prague, Czechia
Research Site — Teplice, Czechia
Research Site — Angers, France
Research Site — Clermont-Ferrand, France
Research Site — Garches, France
Research Site — Grenoble, France
Research Site — Le Chesnay, France
Research Site — Lille, France
Research Site — Limoges, France
Research Site — Lyon, France
Research Site — Nantes, France
Research Site — Orléans, France
Research Site — Pierre-Bénite, France
Research Site — Poitiers, France
Research Site — Rennes, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.